MARKET

GHRS

GHRS

Gh Research Plc
NASDAQ
11.08
-0.22
-1.95%
Closed 16:00 04/24 EDT
OPEN
11.37
PREV CLOSE
11.30
HIGH
11.37
LOW
10.85
VOLUME
45.26K
TURNOVER
0
52 WEEK HIGH
14.64
52 WEEK LOW
5.05
MARKET CAP
576.47M
P/E (TTM)
-16.1965
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at GHRS last week (0415-0419)?
Weekly Report · 3d ago
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist on Hearings. The Drug Enforcement Administration is revisiting its stance on the classification of two psychedelic compounds. The agency has proposed both be listed as Schedule I substances with no recognized medical use. Benzinga Psychedelics Podcast features an expert on the ancient healing plant kanna.
Benzinga · 04/17 12:42
Weekly Report: what happened at GHRS last week (0408-0412)?
Weekly Report · 04/15 10:19
Weekly Report: what happened at GHRS last week (0401-0405)?
Weekly Report · 04/08 10:22
Weekly Report: what happened at GHRS last week (0325-0329)?
Weekly Report · 04/01 10:21
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Utah hospitals will soon provide psilocybin and MDMA therapy for mental health conditions in a pilot program. Beckley Psytech and atai announce positive initial results from a clinical trial of 5-MeO-DMT in Treatment Resistant Depression. Prosecutors in Virginia are probing whether Facebook's social media platforms are facilitating the illegal sale of drugs. Elon Musk makes the case for using psychedelics in a new episode of the Benzinga Psychedelics Podcast.
Benzinga · 03/29 16:43
Weekly Report: what happened at GHRS last week (0318-0322)?
Weekly Report · 03/25 10:23
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement. Psychedelics biopharma company Cybin Inc. Announced that the FDA has granted it a breakthrough therapy designation for its LSD-based treatment for anxiety disorder. The company also announced the pricing of an underwritten offering of $175 million in shares.
Benzinga · 03/20 18:49
More
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.

Webull offers GH Research PLC stock information, including NASDAQ: GHRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GHRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GHRS stock methods without spending real money on the virtual paper trading platform.